Method for increasing HDL cholesterol level

Details Method for increasing HDL cholesterol level Method for increasing HDL cholesterol level

2006-07-11

2006-07-11

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S197110

Reexamination Certificate

active

07074407

ABSTRACT:
The present invention provides a method for increasing HDL cholesterol in a mammal by stimulating an immune response that inhibits the function of CETP. Such an immune response can be induced by immunizing with CETP or fragments of CETP (together termed “CETP Peptides”) which contain an epitope capable of stimulating such a response. The peptides can be conjugated to a carrier, such as KLH or ovalbumin, in order to increase immunogenicity. Adjuvants can also be administered.

REFERENCES:
patent: 5242687 (1993-09-01), Tykocinskli et al.
patent: 5264341 (1993-11-01), Maciak et al.
patent: 5279540 (1994-01-01), Davidson
patent: 5338829 (1994-08-01), Weiner et al.
patent: 5705388 (1998-01-01), Couture et al.
patent: 5843446 (1998-12-01), Ladd et al.
patent: 5994310 (1999-11-01), Buettner et al.
patent: 6143305 (2000-11-01), Stevens
patent: 6284533 (2001-09-01), Thomas
patent: 6410022 (2002-06-01), Rittershaus
patent: 0343460 (1989-11-01), None
patent: 0752886 (1998-01-01), None
patent: WO 90/15627 (1990-12-01), None
patent: WO 92/10203 (1992-06-01), None
patent: WO 93/11782 (1993-06-01), None
patent: WO 93/23076 (1993-11-01), None
patent: WO 94/24567 (1994-10-01), None
patent: WO 94/25060 (1994-11-01), None
patent: WO 95/04755 (1995-02-01), None
patent: WO 95/05849 (1995-03-01), None
patent: WO 96/15141 (1996-05-01), None
patent: WO 96/34888 (1996-11-01), None
patent: WO 96/39168 (1996-12-01), None
patent: WO 97/41227 (1997-11-01), None
Abbey and Calvert, “Effects of Blocking Plasma Lipid Transfer Protein Activity in the Rabbit,”Biochimica et Biophysica Acta.1003:20-29 (1989).
Barter et al.,Biochimica et Biophysica Acta, 531:233-236 (1978).
Bravo et al.,J. Biochem.116:1088-1095 (1994).
Evans et al., “Inhibition of Cholesteryl Ester Transfer Protein in Normocholesterolemic and Hypercholesterolemic Hamsters: Effects on HDL Supspecies, Quantity, and Apolipoprotein Distribution,”J. Lipid Res.35:1634-1645 (1994).
Gaur et al., “Bypass by an Alternate ‘Carrier’ of Acquired Autoimmunity From Pathogenic to Preventive,”International Immunology2:151-155 (1990).
Lasunción et al., “High-Density Lipoprotein Subpopulations As Substrates For The Transfer of Cholesteryl Esters To Very-Low-Density Lipoproteins,”Biochem. J.270:441-449 (1990).
Leff D., “Anti-Atherosclerosis Vaccine Aims to Turn Autoimmunity From Pathogenic to Preventive,”BioWorld Today6(95):1&3 (1995).
Leff,Bioworld Today6(95):1-4 (1995).
Smith et al., “Preparation of an Anti-Peptide Antiserum Specific For Cholesteryl Ester Transfer Protein (CETP),”Med. Sci. Res.21:911-912 (1993).
Swenson et al., “Mechanism of Cholesteryl Ester Transfer Protein Inhibition by a Neutralizing Monoclonal Antibody and Mapping of the Monoclonal Antibody Epitope,”J. Biol. Chem.264:14318-14326 (1989).
Tall A.R., “Plasma Cholesteryl Ester Transfer Protein and High-Density Lipoproteins: New Insights From Molecular Genetic Studies,”J. Internal Medicine237:5-12 (1995).
Tall et al,J. Lipid Res.,27:361-367.
Talwar et al., “A Vaccine That Prevents Pregnancy in Women,”Proc. Natl. Acad. Sci. USA91:8532-8536 (1994).
Wang et al., “Identification of a Sequence Within the C-terminal 26 Amino Acids of Cholesteryl Ester Transfer Protein Responsible for Binding a Neutralizing Monoclonal Antibody and Necesary for Neutral Lipid Transfer Activity,”J. Biol. Chem.267:17487-17490 (1992).
Warnick et al., “A Comprehensive Evaluation of the Heparin-Maganese Precipitation Procedure For Estimating High Density Lipoprotein Cholesterol,”J. Lipid Res.19:65-76 (1978).
Whitlock et al., “Monoclonal Antibody Inhibition of Cholesteryl Ester Transfer Protein Activity in the Rabbit,”J. Clin. Invest.84:129-137 (1989).
Yen et al., “Inhibition of Cholesteryl Ester Transfer Protein Activity by Monoclonal,”J. Clinical Investigation83(6):2018-2024.
Albers et al.,Arteriosclerosis, 4: 49-58 (1984).
Alberts et al.,Molecular Biology of the Cell, 2nded.,(Garland Publishing, Inc., NewYork, NY., 1989) pp. 1006-1007.
Alexander et al.,Immunity, 1: 751-761 (1994).
Bahou et al.,J. Cin. Invest., 84: 56-61 (1989).
Barter et al.,J. Lipid Res., 21: 238-249 (1980).
Bevilacqua et al.,J. Clin. Invest., 91: 379-387 (1993).
Bisgaier et al.,J. Lipid Res., 34: 1625-1634 (1993).
Bisgaier et al.,J. Lipid Res., 32: 21-23 (1991).
Breslow et al.,Proc. Natl. Acad. Sci. USA, 90: 8314-8318 (1993).
Brown et al.,Nature, 342: 448-451 (1989).
Burtis and Ashwood, eds.,Tietz Textbook of Clinical Chemistry, second edition(W.B. Saunders Co., Philadelphia, 1994), Table 41-20.
Carlsson et al.,Biochem. J., 173: 723-737 (1978).
Casali et al.,Science, 234: 476-479 (1986).
Castelli et al.,J. Am. Med. Assoc., 256: 2835-2838 (1986).
Drayna et al.,Nature, 327: 632-634 (1987).
Eldridge et al., inImmunobiology of Proteins and Peptides V: Vaccines; Mechanisms, Design, and Applications, Atassi, M.Z., ed. (Plenum Press, New York, 1989), pp. 191-202.
Engelhard, Victor H.,Sci. Am., 54-60 (1994).
Etlinger et al.,Science, 249: 423-425 (1990).
Etlinger, H.,Immunol. Today, 13: 52-55 (1992).
Fielding et al.,J. Lipid Res., 36: 211-228 (1995).
Gavish et al.,J. Lipid Res., 28: 257-267 (1987).
Gaynor et al.,Atherosclerosis, 110: 101-109 (1994).
Gordon et al.,N. Engl. J. Med., 321: 1311-1316 (1989).
Green et al.,Cell, 28: 477-487 (1982).
Greenspan & Baxter, eds.,Basic and Clinical Endocrinology 4thed., (Appleton & Lange, Inc., Norwalk, Connecticut, 1994), p. 432 (referring to the specifics of Gonadotropin-Releasing hormone).
Guyard-Dangremont et al.,Chim. Clin. Acta, 231: 147-160 (1994).
Ha et al.,Biochim. Biophys. Acta, 833: 203-211 (1985).
Ha et al.,Comp. Biochem. Physiol., 83B: 463-466 (1986).
Havel et al., “Introduction: Structure and metabolism of plasma lipoproteins”, InThe Metabolic Basis of Inherited Disease, 6th ed., pp. 1129-1138 (Scriver, et al., eds.) (McGraw-Hill, Inc., New York, 1989).
Hayek et al.,J. Clin. Invest., 90: 505-510 (1992).
Hayek et al.,J. Clin. Invest., 91: 1665-1671 (1993).
Hesler et al.,J. Biol. Chem., 263: 5020-5023 (1988).
Hesler et al.,J. Biol. Chem., 262: 2275-2282 (1987).
Hopp and Woods,Proc. Natl. Acad. Sci. USA, 78: 3824-3828 (1981).
Ikewaki, et al.,J. Clin. Invest., 96: 1573-1581 (1995).
Inazu et al.,N. Engl. J. Med., 323: 1234-1238 (1990).
Jameson and Wolf,CABIOS, 4: 181-185 (1988).
Jarnagin et al.,Proc. Natl. Acad. Sci. USA, 84: 1854-1857 (1987).
Jiang et al.,J. Biol. Chem., 266: 4631-4639 (1991).
Jiang et al.,J. Biol. Chem., 268: 27406-27412 (1993).
Jorieux et al.,Brit. J. of Haematology, 87: 113-118 (1994).
Kligfield et al.,Am. Heart J., 112(3): 589-597 (1986).
Korn et al.,J. Mol. Biol., 65: 525-529 (1972).
Kushwaha et al.,J. Lipid Res., 34: 1285-1297 (1993).
Madden et al.,Ann. Rev. Immunol., 13: 587-622 (1995).
Mader, S.S., InHuman Biology, 4th ed., pp. 83, 102 (Wm. C. Brown Publishers, Dubuque, Iowa, 1995).
Marguerite et al.,Mol. Immunol., 29: 793-800 (1992).
Marotti et al.,Nature, 364: 73-75 (1993).
Mathews, C.K. and van Holde, K.E.,Biochemistry, pp. 574-576, 626-630 (The Benjamin/Cummings Publishing Co., Redwood City, California, 1990).
Means and Feeney,Bioconjugate Chem., 1: 2-12 (1990).
Mezdour et al.,Clin. Chem. 40/4: 593-597 (1994).
Michel et al.,Am. Heart J. 117(3): 756-767 (1989).
Miller et al.,Am. Heart J., 113: 589-597 (1987).
Nagashima et al.,J. Lipid Res., 29: 1643-1649 (1988).
Palker et al.,Proc. Natl. Acad. Sci. USA, 84: 2479-2483 (1987).
Panina-Bordignon et al.,Eur. J. Immunol., 19: 2237-2242 (1989).
Pruitt et al.,J. Surg. Res., 50: 350-355 (1991).
Pruitt et al.,Transplantation, 52: 868-873 (1991).
Quig et al.,Ann. Rev. Nutr., 10: 169-193 (1990).
Quinet et al.,J. Clin. Invest., 85: 357-363 (1990).
Raju et al.,Eur. J. Immunol., 25: 3207-3214 (1995).
Rosen et al.,J. Immunol. Methods,172: 135-137 (1994).
Rye et al.,J. Biol. Chem., 270: 189-196 (1995).
Sad et al.,Immunol., 76: 599-603 (1992).
Stern et al.,Nature, 368: 215-221 (1994).
Suckling, Keith E.,Bio/Technology, 12

Affiliated with

Also associated with

Rating

Method for increasing HDL cholesterol level does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for increasing HDL cholesterol level, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for increasing HDL cholesterol level will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3581870